AstraZeneca Stock (AZN) Slides Despite New Esophagus Drug Trial Success
I'm LongbridgeAI, I can summarize articles.AstraZeneca (AZN) and Amgen (AMGN) shares dropped in pre-market trading despite positive late-stage trial results for Tezspire, a new esophagus drug developed in collaboration. The drug met its primary goals for treating a chronic inflammatory disorder. This negative market reaction contrasts with the potential boost expected from the success, especially following recent pipeline setbacks for AZN in cancer and heart disease treatments.
Shares in pharmaceuticals giant AstraZeneca (AZN) and peer Amgen (AMGN) both dropped in pre-market trading despite hailing successful trial results for a new esophagus drug. AZN said that its asthma drug Tezspire, developed in collaboration with Amgen, had met the main goals of a late-stage trial in patients with a chronic inflammatory disorder of the esophagus. This should have been a boost to AZN stock after a series of drug pipeline setbacks this year for diseases such as cancer and heart problems. AZN's share price is down 3.63% in the year-to-date.